Pharmacy

Controversy surrounds Exondys 51 approval: What to knowNew medicine for Duchenne muscular dystrophy raises questions. Here’s whose covering it and why.
Brace for a barrage of biosimilarsThe next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.
Three ways integration focuses on customersHere are three ways HealthPartners’ health plan and care delivery system work together to save customers time and money and improve their experience.
Top 3 factors in biosimilar coverageAn Avalere study has interesting findings about payer acceptance of biosimilars.
Clinical pharmacists gain prominence as the industry changes
Clinical pharmacists gain prominence as the industry changesPayers realize value in partnering with pharmacists to manage medication-related complications
Five ways to combat growing polypharmacy among childrenOne expert believes managed care executives are key to a necessary paradigm shift in pediatric polypharmacy.
Two strategies to help consumers lower drug costsHealthPartners aims to improve price information for consumers. Here’s how.
Four ways PBMs must change to thrive in the future
Four ways PBMs must change to thrive in the futureThe days of the traditional, channel-focused and largely enshrouded PBM business model have come and gone. Here’s what’s next.
Can Amazon change the pharmacy landscape?Industry experts analyze issues of mail delivery and transparency in the prescription drug market.
Top 3 strategies employers should use to decrease healthcare costsA new Willis Towers Watson survey finds that U.S. employers have three key strategies to building cost-effective healthcare programs.